Add this to the list of hydroxychloroquine (HCQ) letdowns in managing COVID-19 treatment or risk - prophylaxis with HCQ fails to prevent COVID-19 infection in those exposed to the SARS-CoV-2 virus.
NEJM has reported a prospective, randomized, double-blind, placebo-controlled trial from the US and Canada wherein adults with household or occupational exposure to someone with confirmed Covid-19 were treated with either placebo or HCQ within
Several recent reports offer conflicting views on the potential benefits and adverse outcomes of IL-6 inhibition with tocilizumab (TCZ) therapy in patients with severe COVID-19 infection.
An Italian study grabbed the headlines yesterday with a press release stating TCZ did not improve respiratory symptoms, ICU admissions or mortality rates when given to 126 COVID patients with early disease. The study, supported by the Italian Medicines Agency
Dr. John Cush RheumNow
6 years 3 months ago
Early COVID 1255 patients In Wuhan, China - median age 64 yrs; 53 male: 63% w/ chronic comorbidities. There were 17 autoimmune pts w/ COVID () - median age 64; 83% female; only 1 admitted to ICU and one died. 10 stopped DMARDS & 5 their Dz worsened https://t.co/1KgU9tYUqV
Dr. John Cush RheumNow
6 years 3 months ago
NGF inhibitor Tanuzemab (TNZ) phase III study in patients with low back pain - H2H against placebo and tramadol. At 16 wks, ≥50% improvement in LBPI was 37%, 43% TNZ 5mg and 46% TNZ 10mg (Odds ratio [95% CI] vs placebo = 1.45 [1.09, 1.91; P=0.0101]). https://t.co/3DvUHtxcqk
Eric Topol EricTopol
6 years 3 months ago
The 5 states with the highest slope of case increasing, per million population, June 20th
1. Arizona (way out in front)
2. South Carolina
3. Florida
4. Texas
5. Oklahoma (pre-rally) https://t.co/M1PsBgmhJb
Dr. John Cush RheumNow
6 years 3 months ago
#EULAR2020 Round-Up w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb
Dr. John Cush RheumNow
6 years 3 months ago
RheumNow Podcast is Up! New FDA approvals for secuminumab, canakinumab, risk of GI perforations, tocilizumab in COVID, Weaning DMARDs/Biologics and Blacks with AS. Watch here>> https://t.co/2fTQPJ5iSr Listen to the podcast on Soundcloud>> https://t.co/uPklKQEauE
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Dr. John Cush RheumNow
6 years 3 months ago
Study of 260 pts with cutaneous lupus shows higher CLASI (skin activity) scores were associated with smoker, higher CRP, and chronic CLE disease https://t.co/X1eJel9CLP
Dr. John Cush RheumNow
6 years 3 months ago
Congratulations to Christopher Buckley, Kennedy Professor of Translational Rheumatology at the University of Birmingham and Oxford, for being awarded the 2020 Carol Nachman prize for Rheumatology https://t.co/xis9RmsoCf
Yesterday the FDA approved secukinumab (Cosentyx) for the treatment of patients with active non-radiographic axial spondyloarthritis (nr-axSpA). There are now three agents that are FDA approved for nr-axSpA: certolizumab, ixekizumab and now, secukinumab.
TNR Grand Rounds - Cytokine Storm Syndrome
Randy Cron, MD, PhD, presents Tuesday Nite Rheumatology: Cytokine Storm Syndrome.
The high potency calcineurin inhibitor voclosporin plus standard of care was superior to standard of care alone in a phase III study of lupus nephritis known as AURORA.
Dr. John Cush RheumNow
6 years 3 months ago
African-Americans with Ank Spondylitis have worse disease compared to whites. Study of 10,990 AS patients shows AA to have high frequency of anterior uveitis, hypertension, diabetes, depression, and heart disease and higher ESR and CRP levels. https://t.co/YyLqlM85sD
